JCO Goes to Twice-Monthly Schedule

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

ALEXANDRIA, Va-The Journal of Clinical Oncology (JCO) has doubled the number of issues it publishes each year, but not the number of articles it will accept. The JCO, a publication of the American Society of Clinical Oncology (ASCO), now publishes two issues monthly, one mailed in the middle and the other at the end of the month.

ALEXANDRIA, Va—The Journal of Clinical Oncology (JCO) has doubled the number of issues it publishes each year, but not the number of articles it will accept. The JCO, a publication of the American Society of Clinical Oncology (ASCO), now publishes two issues monthly, one mailed in the middle and the other at the end of the month.

Increasing the journal’s publication frequency will shorten the time between the acceptance and publication of studies. However, the number of articles published will remain the same. “We’re halving the size of the journal to make it more portable and easier for subscribers to read cover to cover,” said editor George P. Canellos, MD.

Articles in this issue
IL-13 Used to Deliver Bacterial Toxin to Brain Tumors in Mice
BAG-1 Overexpression Has a ‘Paradoxical’ Association With Improved Breast Cancer Survival
Rituximab/CHOP Combo Effective in Low-Grade NHL
3D CT-Guided Seminal Vesicle Biopsy for Staging
Elderly Patients Tolerate Breast Cancer Therapy
Coaxial Breast Biopsy Device Provides Diagnostic Specimens
3D Digital Camera Accurately Calculates Breast Shape, Volume
Thermoacoustic CT Under Development for Breast Imaging
Early Local Recurrence After Lumpectomy Predicts Metastasis
Panel Recommends Listing 9 Substances in Carcinogen Report
State of the Union on Youth Smoking ‘Clearly Not Good’
Low-Dose CT Screening Detects NSCLC: ELCAP Update
Mandatory HIV Testing of Newborns Not Routine: HHS
ASCO Launches Large-Scale Study on Quality of Cancer Care
Advocate Urges Greater Attention to Cancer Prevention Research
Recent Videos
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Related Content
Explore how oncogenes and signaling pathways converge and diverge in cancer, shaping diagnostic and therapeutic strategies for personalized interventions.

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology

Aliasgar Shahiwala, PhD
October 25th 2025
Article

Explore how oncogenes and signaling pathways converge and diverge in cancer, shaping diagnostic and therapeutic strategies for personalized interventions.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.

ROS1-Targeting Therapies Show “Suboptimal” Efficacy in ROS1-Mutated NSCLC

Roman Fabbricatore
October 24th 2025
Article

Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

FDA Grants BTD to Zenocutuzumab in NRG1+ Cholangiocarcinoma

FDA Grants BTD to Zenocutuzumab in NRG1+ Cholangiocarcinoma

Ariana Pelosci
October 24th 2025
Article

For patients with NRG1+ cholangiocarcinoma, zenocutuzumab may be a therapy option, according to results from the phase 2 eNRGY trial.

Notably, improvements in both the ESR1 mutated population and the intent-to-treat population, including ESR1 wild type, were announced, and data will be presented at an upcoming scientific meeting.

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

Neil M. Iyengar, MD
October 24th 2025
Article

Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.